At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
gemcitabine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
In Brief
A Phase 2 clinical trial evaluating gemcitabine, docetaxel, and 1 other intervention for Sarcoma and 4 related conditions. Completed, enrolled 47 participants across 1 site.
Detailed Summary
The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionOct 2014
Study CompletionNov 2014
TodayJul 2026
First PostedApr 24, 2009
Enrollment StartApr 1, 2009
Primary CompletionOct 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 17.2 years ago
Interventions
gemcitabinedrug
docetaxeldrug
bevacizumabdrug